Last Price
0.318
Today's Change
-0.007 (2.15%)
Day's Change
0.31 - 0.336
Trading Volume
438,590
Overview
Market Cap
779,481
Shares Outstanding
2 Million
Avg Volume
3,375,798
Avg Price (50 Days)
0.52
Avg Price (200 Days)
2.55
PE Ratio
-0.02
EPS
-14.43
Earnings Announcement
07-Aug-2023
Previous Close
0.32
Open
0.33
Day's Range
0.31 - 0.3362
Year Range
0.301 - 14.22
Trading Volume
438,590
Price Change Highlight
1 Day Change
-2.06%
5 Day Change
-11.67%
1 Month Change
0.57%
3 Month Change
-64.63%
6 Month Change
-90.59%
Ytd Change
-93.75%
1 Year Change
-91.38%
3 Year Change
-99.80%
5 Year Change
-99.73%
10 Year Change
-99.73%
Max Change
-99.73%
News and Blogs
No result.
Company Profile
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Featured Posts
12
Apps
Top Articles
1
NordFX Weekly Forecast
Forex and Cryptocurrency Forecast for September 09 – 13, 2024
2
CEO Morning Brief
Ultra-rich Families Set to Control US$9.5 Tril by 2030, Says Deloitte
3
CEO Morning Brief
4
CEO Morning Brief
5
CEO Morning Brief
US Trade Deficit Widens to US$78.8 Bil, Largest in Two Years
#
Stock
Score
Daily Stocks
Stock
Last
Change
Volume
Stock
Last
Change
Volume
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
